Ishita Drugs & Industries Ltd
₹ 78.0
-0.24%
10 Jun
- close price
About
Incorporated in 1992, Ishita Drugs & Industries Limited is the flagship company of ISHITA group. It is engaged in manufacture of various Active Pharma Ingredients, drug intermediates, fine chemicals and excipients.
Key Points
- Market Cap ₹ 23.3 Cr.
- Current Price ₹ 78.0
- High / Low ₹ 105 / 62.2
- Stock P/E 26.8
- Book Value ₹ 36.1
- Dividend Yield 0.00 %
- ROCE 9.91 %
- ROE 8.40 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 0.23% over past five years.
- Company has a low return on equity of 7.64% over last 3 years.
- Earnings include an other income of Rs.0.34 Cr.
- Working capital days have increased from 101 days to 208 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.34 | 7.54 | 7.10 | 6.44 | 6.90 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 | 15.19 | 15.00 | |
| 6.89 | 7.23 | 6.82 | 6.08 | 6.45 | 8.57 | 14.07 | 13.03 | 13.01 | 11.31 | 14.28 | 14.01 | |
| Operating Profit | 0.45 | 0.31 | 0.28 | 0.36 | 0.45 | 0.52 | 0.76 | 0.92 | 1.08 | 0.76 | 0.91 | 0.99 |
| OPM % | 6.13% | 4.11% | 3.94% | 5.59% | 6.52% | 5.72% | 5.12% | 6.59% | 7.67% | 6.30% | 5.99% | 6.60% |
| 0.00 | 0.17 | 0.13 | 0.08 | 0.12 | 0.16 | 0.16 | 0.31 | 0.11 | 0.20 | 0.28 | 0.34 | |
| Interest | 0.03 | 0.04 | 0.06 | 0.04 | 0.11 | 0.06 | 0.03 | 0.03 | 0.02 | 0.05 | 0.09 | 0.07 |
| Depreciation | 0.12 | 0.15 | 0.15 | 0.14 | 0.14 | 0.16 | 0.18 | 0.15 | 0.13 | 0.13 | 0.11 | 0.11 |
| Profit before tax | 0.30 | 0.29 | 0.20 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 | 0.99 | 1.15 |
| Tax % | 33.33% | 24.14% | 30.00% | 30.77% | 25.00% | 26.09% | 23.94% | 20.95% | 23.08% | 25.64% | 24.24% | 25.22% |
| 0.20 | 0.22 | 0.14 | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.80 | 0.58 | 0.75 | 0.87 | |
| EPS in Rs | 0.67 | 0.74 | 0.47 | 0.60 | 0.84 | 1.17 | 1.84 | 2.78 | 2.68 | 1.94 | 2.51 | 2.91 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 0% |
| 3 Years: | 2% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 10% |
| 3 Years: | 3% |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 42% |
| 3 Years: | 17% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 2.28 | 2.50 | 2.64 | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 | 6.93 | 7.80 |
| 0.19 | 0.09 | 1.13 | 0.01 | 0.13 | 0.20 | 0.29 | 0.04 | 0.00 | 0.96 | 0.00 | 3.90 | |
| 1.15 | 1.37 | 1.43 | 1.37 | 0.97 | 1.73 | 2.30 | 1.43 | 2.66 | 1.27 | 0.89 | 1.61 | |
| Total Liabilities | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.30 |
| 1.36 | 1.26 | 1.11 | 1.02 | 1.19 | 1.30 | 1.14 | 1.00 | 0.88 | 0.89 | 0.80 | 0.88 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.45 | 1.82 | 2.15 | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 | 3.34 | 3.87 |
| 3.80 | 3.87 | 4.93 | 3.47 | 2.82 | 3.00 | 3.12 | 5.15 | 6.32 | 7.12 | 6.67 | 11.55 | |
| Total Assets | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.30 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.73 | 0.11 | 0.26 | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 | 2.12 | -3.64 | |
| -0.45 | -0.34 | -0.28 | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 | 0.13 | -0.67 | |
| 0.03 | -0.07 | 1.07 | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0.00 | 1.05 | -0.87 | 4.33 | |
| Net Cash Flow | 0.31 | -0.29 | 1.05 | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 | 1.38 | 0.02 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52.21 | 60.51 | 96.65 | 96.35 | 43.38 | 47.38 | 32.24 | 39.77 | 13.99 | 54.43 | 16.82 | 46.23 |
| Inventory Days | 73.00 | 91.60 | 55.65 | 51.49 | 55.56 | 42.20 | 18.49 | 23.06 | 34.81 | 68.22 | 34.27 | 152.28 |
| Days Payable | 69.24 | 78.31 | 91.07 | 108.49 | 43.21 | 78.70 | 60.25 | 34.76 | 73.22 | 36.67 | 14.87 | 32.44 |
| Cash Conversion Cycle | 55.98 | 73.80 | 61.23 | 39.35 | 55.72 | 10.88 | -9.52 | 28.07 | -24.41 | 85.99 | 36.22 | 166.08 |
| Working Capital Days | 57.68 | 64.38 | 67.35 | 57.24 | 32.27 | 8.03 | -6.65 | 29.83 | -27.46 | 71.97 | 21.87 | 208.29 |
| ROCE % | 6.72% | 5.98% | 4.21% | 4.77% | 7.16% | 8.12% | 10.68% | 14.32% | 12.90% | 8.86% | 10.77% | 9.91% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015
3h - Board meeting on 13 June 2025 to discuss current business operations and other matters.
-
Outcome Of Board Meeting Held On 30Th May, 2025
30 May - Approved FY25 audited results, appointed secretarial auditor for 5 years, re-appointed internal auditors.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Board approved FY25 audited results, appointed secretarial auditor, re-appointed internal auditors, unmodified audit opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th May, 2025
30 May - Approved audited FY25 financials; appointed secretarial auditor for 5 years; unmodified audit opinion.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter And Year Ended 31St March 2025
23 May - Board meeting on 30 May to approve FY25 results, re-appointments, and governance reports.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:[1]
a) Active Pharma Ingredients: Sulfa Drugs / Sulfonamides, Vitamins, Fluoro Quinolones, Antibiotics, Anthelmintics, Iodides & Citrates (Salts), Food Additives / Excipients, etc.
b) Drug Intermediates: Sulfonamido Phenyl, Chloro Phenyl, Hydroxy Methyl, Dimethyl Benzil, Phenyl Coumarin
c) Fine Chemicals: Salicylanilide, Para Bromo Toluene 99.5%, Pyridine Hydrobromide, Nicotinic Acid Hydrazide